Abstract
Background Hospitalized patients with COVID-19 experience high mortality rates, ranging from 10% to 30%. Combined casirivimab and imdevimab (CAS+IMD) is authorized for use in outpatients with COVID-19 and in post-exposure prophylaxis. The UK-based platform RECOVERY study reported improved survival in hospitalized seronegative patients treated with CAS+IMD; however, in most of the world, anti-spike monoclonal antibody therapy is currently not approved for hospitalized patients.
Methods In this phase I/II/III double-blind placebo-controlled trial, patients hospitalized with COVID-19 were randomized (1:1:1) to 2.4 g or 8.0 g of CAS+IMD or placebo, and characterized at baseline for viral load and SARS-CoV-2 endogenous immune response.
Results 1336 patients on low-flow or no supplemental oxygen were treated. The primary endpoint was met: in seronegative patients, the least squares mean difference (CAS+IMD vs placebo) for time-weighted average change from baseline viral load was –0.28 log10 copies/mL (95% confidence interval [CI] –0.51 to –0.05; P = .0172). The primary clinical analysis of death or mechanical ventilation from day 6 to 29 in patients with high viral load had a strong positive trend but did not reach significance. CAS+IMD numerically reduced all-cause mortality in seronegative patients through day 29 (relative risk reduction, 55.6%; 95% CI 24.2–74.0; nominal P = .0032). No safety concerns were noted.
Conclusions In hospitalized patients with COVID-19 on low-flow or no oxygen, CAS+IMD treatment reduced viral load and the risk of death or mechanical ventilation as well as all-cause mortality in the overall population, with the benefit driven by seronegative patients and no harm observed in seropositive patients.
Competing Interest Statement
ICMJE disclosure forms provided by the authors are available with the full text of this article
Clinical Trial
NCT04426695
Funding Statement
Supported by Regeneron Pharmaceuticals, Inc. Certain aspects of this project have been funded in whole or in part with federal funds from the Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response, and Biomedical Advanced Research and Development Authority, under OT number HHSO100201700020C.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics approval was obtained from the following ethics review boards: Comissao de Etica para Analise de Projetos de Pesquisa do HCFMUSP, Sao Paulo, Brazil; Comite De Etica Em Pesquisa Prof. Dr. Celso Figueiroa Hospital, Salvador, Bahia, Brazil; Comite de Etica em Pesquisa da Faculdade de Medicina de Botucatu, Sao Paulo, Brazil; Comite de Etica em Pesquisa da Universidade de Passo Fundo, Rio Grande do Sul, Brazil; Comite de Etica em Pesquisa Envolvendo Seres Humanos da Universidade Comunitaria da Servidao Anjo da Guarda, Santa Catarina, Brazil; Comite de Etica em Pesquisa do Instituto Dante Pazzanese de Cardiologia, Sao Paulo, Brazil; Comite de Etica em Pesquisa emSeres Humanos do Hospital das Clinicas da UFPR, Parana, Brazil; Comite de Etica em Pesquisa do Conjunto Hospitalar do Mandaqui, Sao Paulo, Brazil; Comite de Etica de la Investigacion de Clinica Las Condes, Santiago, Chile; Comite Etico Cientifico Facultad de Medicina Clinica Alemana Universidad del Desarrollo, Santiago, Chile; Comite de Etica en Investigacion del Nuevo Hospital Civil de Guadalajara "Dr. Juan I Menchaca", Guadalajara, Mexico; Comite de Etica en Investigacion del Centro de Especialidades Medicas del Sureste, Merida, Yucatan, Mexico; Comite de Etica en Investigacion del Hospital General de Culiacan, Culiacan, Mexico; Comite de Etica en Investigacion de Medica Sur, S.A.B de C.V., Ciudad de Mexico, Mexico; Comite de Etica en Investigacion del Hospital La Mision, Monterrey, Mexico; Hospital General de Occidente, Zapopan, Mexico; National Centre of Health Management, Chisinau, Republic of Moldova; Comisia Nationala de Bioetica a Medicamentului si Dispozitivelor Medicale, Bucuresti, Romania; Western Institutional Review Board, Puyallup, WA, USA; Providence St. Joseph Institutional Review Board, Renton, WA, USA; Tufts Health Sciences IRB, Boston, MA, USA; Providence Health and Services IRB, Portland, OR, USA; Lifespan IRB, Providence, RI, USA; St. Vincent Hospital and Health Care Center, Inc., Office of Clinical Trials, Indianapolis, IN, USA; BRANY, New Hyde Park, NY, USA; Institutional Review Board, University of Nebraska Medical Center, Omaha, NE, USA; Spectrum Health IRB, Grand Rapids, MI, USA; Research Compliance Office, Stanford University, Palo Alto, CA, USA; and Providence St. Joseph Health (PSJH) Institutional Review Board, Irvine, CA, USA.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵b Former employee of Regeneron Pharmaceuticals, Inc.
Data Availability
Qualified researchers may request access to study documents (including the clinical study report, study protocol with any amendments, blank case report form, and statistical analysis plan) that support the methods and findings reported in this manuscript. Individual anonymized participant data will be considered for sharing once the indication has been approved by a regulatory body, if there is legal authority to share the data and there is not a reasonable likelihood of participant re-identification. Submit requests to https://vivli.org/.
